List of Excipients in Branded Drug MAGNESIUM SULFATE IN 5% DEXTROSE

Generic Drugs Containing MAGNESIUM SULFATE IN 5% DEXTROSE

Company	Ingredient	NDC	Excipient
Fresenius Kabi USA LLC	magnesium sulfate heptahydrate	63323-108	DEXTROSE MONOHYDRATE
Fresenius Kabi USA LLC	magnesium sulfate heptahydrate	63323-108	SODIUM HYDROXIDE
Fresenius Kabi USA LLC	magnesium sulfate heptahydrate	63323-108	SULFURIC ACID

What are the Most Frequently-Used Excipients in MAGNESIUM SULFATE IN 5% DEXTROSE?

# Of NDCs	Excipient
1	DEXTROSE MONOHYDRATE
1	SODIUM HYDROXIDE
1	SULFURIC ACID

Magnesium Sulfate in 5% Dextrose: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 9, 2026

Magnesium sulfate in 5% dextrose is a mature, low-complexity sterile injectable product with limited conventional patent protection. Commercial value is concentrated in reliable supply, ready-to-administer packaging, pharmacy workflow, shortage resilience, and differentiated presentations rather than in the magnesium sulfate molecule. The core formulation has a narrow technical design space: magnesium sulfate must remain soluble and stable in an aqueous dextrose vehicle, while the finished product must meet sterility, particulate, osmolality, container-closure, and labeling requirements.

What is magnesium sulfate in 5% dextrose used for?

Magnesium sulfate in 5% dextrose is an intravenous solution used when magnesium replacement or magnesium-mediated treatment is required and a dextrose-containing vehicle is acceptable. Clinical uses include hypomagnesemia, preeclampsia and eclampsia management, torsades de pointes, selected asthma protocols, and other hospital-based indications governed by institutional protocols.

The formulation generally contains:

Component	Function
Magnesium sulfate, commonly as the heptahydrate	Active pharmaceutical ingredient and source of magnesium ions
Dextrose 5% in water	Vehicle, tonicity contributor, and carbohydrate source
Water for Injection	Solvent
pH adjusters, where used	pH control
Preservatives	Generally absent in single-dose intravenous premixes

Magnesium sulfate injection labels warn about intravenous administration rate, renal impairment, hypermagnesemia, and monitoring requirements. The product is administered in a controlled clinical setting rather than sold as a conventional retail medicine. FDA-approved labeling identifies concentration, route, warnings, storage, and compatibility requirements for the specific presentation. [1]

What excipients are used in magnesium sulfate 5% dextrose formulations?

The principal excipient is dextrose. The formulation normally has a minimal excipient profile because the product is a sterile, parenteral solution intended for intravenous administration.

Dextrose as the primary vehicle

Dextrose 5% in water provides approximately 50 mg/mL dextrose. Its commercial functions are:

• Providing a familiar hospital fluid vehicle
• Supporting a ready-to-administer presentation
• Contributing to solution tonicity
• Differentiating the product from magnesium sulfate in water for injection or sodium chloride presentations
• Supporting use in protocols where saline loading is undesirable

Dextrose is not an inert commercial choice. It affects osmolality, labeling, storage, compatibility, and patient selection. A dextrose-containing product may be unsuitable or less attractive for patients with hyperglycemia, diabetes, or clinical conditions where glucose administration is limited.

pH adjustment

Magnesium sulfate solutions are typically formulated within a controlled pH range appropriate for intravenous administration and product stability. A manufacturer may use a small quantity of acid or base for pH adjustment, but the specific excipient and concentration depend on the approved formulation.

pH adjustment can affect:

• Magnesium sulfate solubility
• Container compatibility
• Degradation pathways involving dextrose
• Visual appearance
• Injection-site tolerability
• Stability during terminal sterilization or extended storage

A pH-adjusted product should not be treated as interchangeable with every magnesium sulfate solution solely because the active concentration is identical.

Preservative strategy

Preservative-free design is generally preferred for intravenous magnesium sulfate premixes. A preservative can create regulatory, toxicological, and compatibility burdens, particularly for neonates, critically ill patients, and repeated-dose hospital protocols.

A single-dose bag or bottle can support a simpler label and lower preservative-related risk. Multi-dose presentations may create a different regulatory and microbiological profile, but they are less attractive for many hospital intravenous applications.

What formulation attributes create commercial differentiation?

The strongest opportunities are operational rather than molecular. A successful product should reduce preparation steps, medication errors, waste, or pharmacy labor.

Concentration and dose flexibility

Hospitals may use different magnesium sulfate doses and infusion volumes. Commercial presentations can be differentiated through:

• Low-dose premixes for routine replacement
• Higher-dose premixes for obstetric emergencies
• Small-volume bags for rapid protocol execution
• Larger-volume bags for controlled infusion
• Multiple concentrations that reduce bedside dilution
• Ready-to-use formats that eliminate pharmacy compounding

The product must balance dose flexibility against inventory complexity. Too many strengths increase stocking costs and the risk of selecting the wrong bag.

Container-closure system

The container is a major commercial and technical variable. Potential formats include flexible intravenous bags, semi-rigid plastic containers, and other sterile single-dose systems.

The selection affects:

• Product weight and shipping cost
• Port design and administration-set compatibility
• Extractables and leachables
• Oxygen and moisture transmission
• Breakage risk
• Overwrap requirements
• Warehouse handling
• Environmental and disposal considerations

A bag with an integrated administration port and clear labeling can have more practical value than a nominally improved formulation that does not fit hospital workflow.

Premixed versus pharmacy-compounded product

A ready-to-administer premix can displace preparation from central pharmacy or nursing units. The commercial proposition is strongest where hospitals face:

• High magnesium sulfate utilization
• Staffing constraints
• Hazardous or high-risk medication preparation requirements
• Frequent obstetric emergencies
• Medication-error reduction programs
• Intravenous admixture outsourcing costs
• Product shortages affecting standard concentrations

The manufacturer must demonstrate that the premix has an acceptable shelf life and can be stored within existing hospital conditions.

What patents protect magnesium sulfate in 5% dextrose?

The active ingredient and basic solution concept have weak patent potential because magnesium sulfate, dextrose injection, and aqueous intravenous administration are long-established technologies. A new product based only on magnesium sulfate dissolved in 5% dextrose is unlikely to support broad composition-of-matter protection.

Potentially protectable subject matter includes:

Patent category	Potential value
Specific concentration and volume	Low to moderate, depending on novelty and claim scope
Container and port configuration	Moderate if the design solves a defined handling or compatibility problem
Low-degradation formulation	Moderate if supported by comparative stability data
Manufacturing process	Moderate, usually difficult to enforce against independent manufacturing
Sterilization and filling process	Moderate, often better treated as know-how
Extended room-temperature stability	Moderate if technically unexpected
Packaging that limits discoloration or degradation	Moderate
Administration system	Moderate to high when integrated with a broader delivery platform
Clinical method-of-use claim	Generally limited for well-established magnesium indications

The most defensible intellectual property is likely to be a combination of formulation, packaging, and process claims rather than a broad claim to magnesium sulfate in dextrose.

What is the Orange Book status of magnesium sulfate in 5% dextrose?

The Orange Book should be reviewed by exact product name, strength, dosage form, applicant, and application number. FDA approval status for a magnesium sulfate premix may arise through an ANDA, an NDA, or another applicable pathway depending on the reference product and formulation history. Orange Book patent listing is not guaranteed for every approved product.

For this category, an applicant should distinguish among:

1. The approved product application.
2. Any listed patents for the exact product.
3. Drug substance or formulation patents that are expired or absent.
4. Unlisted manufacturing, packaging, or trade-secret protections.
5. State and federal procurement barriers unrelated to patent rights.

Because the formulation is mature, the principal market-entry risks are usually regulatory execution, manufacturing validation, supply reliability, and contracting rather than a broad blocking patent.

When does magnesium sulfate in 5% dextrose lose exclusivity?

There is no single universal loss-of-exclusivity date for all magnesium sulfate in 5% dextrose products. The answer depends on the specific approved application and any applicable regulatory exclusivity.

For a mature generic injectable, the practical exclusivity analysis usually includes:

• Expiration of any listed patents
• Expiration of any applicable new-drug exclusivity
• ANDA approval timing
• First-filer status, if relevant
• Paragraph IV certifications
• 180-day generic exclusivity, where applicable
• Product-specific FDA guidance
• State purchasing contracts and hospital formulary access

Because magnesium sulfate is an old active ingredient with numerous established products, the commercial market is generally open to multiple approved suppliers. FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations and Drugs@FDA are the controlling sources for application and therapeutic-equivalence information. [2,3]

Are Paragraph IV challenges relevant to magnesium sulfate premixes?

Paragraph IV litigation is possible but less likely to create a major barrier in this product class. A challenger would need to target an unexpired listed patent associated with the reference product. The most plausible targets would involve:

• A particular ready-to-use concentration
• A container system
• A stability profile
• A manufacturing process
• A specialized administration configuration

A Paragraph IV challenge against a narrow formulation or packaging patent could affect launch timing, but it would not necessarily prevent entry through a noninfringing presentation. The commercial value of litigation may be limited when hospitals can substitute among magnesium sulfate strengths, vehicles, and manufacturers.

A full diligence review should search FDA patent listings, federal court dockets, ANDA litigation records, and the applicant’s product-specific labeling. No broad patent barrier should be assumed from the existence of a branded or authorized generic product.

What manufacturing and intellectual-property barriers affect market entry?

Manufacturing risk is more material than active-ingredient patent risk.

Sterile manufacturing requirements

The product requires validated sterile manufacturing, aseptic processing or an appropriate terminal sterilization strategy, environmental controls, container-closure integrity testing, and particulate control. FDA’s current sterile-drug manufacturing expectations are described in its aseptic processing guidance. [4]

Critical process variables include:

• Dissolution order and mixing time
• Bulk solution hold time
• Filtration performance
• Filling accuracy
• Terminal sterilization exposure, where applicable
• Container-closure integrity
• Visual inspection
• Endotoxin control
• Stability under labeled storage conditions

Dextrose-related stability

Dextrose solutions can undergo degradation and discoloration under heat, light, oxygen exposure, or unsuitable pH conditions. A manufacturer may gain commercial value from:

• A validated low-discoloration process
• Improved oxygen-barrier packaging
• Controlled headspace
• Shorter thermal exposure
• Light-protective overwrap
• Stability data supporting longer shelf life

These measures may be difficult to convert into broad patent claims but can create an operational advantage and proprietary know-how.

Compatibility

Magnesium sulfate may be incompatible with certain drugs or solutions. Calcium-containing products and alkaline solutions require particular attention because precipitation or incompatibility can occur under defined conditions. The label and institutional compatibility references control clinical use. A manufacturer should avoid making broad compatibility claims without product-specific data.

Which companies are competing in the magnesium sulfate injectable market?

Competition generally includes large generic injectable manufacturers, hospital-supply companies, contract manufacturers, and regional sterile-product suppliers. The relevant competitive set changes by country and by presentation.

The important dimensions are:

Competitive factor	Business impact
FDA-approved product availability	Determines legal market access
Premix concentration	Determines protocol fit
Bag or bottle format	Determines pharmacy and nursing workflow
Shelf life	Affects inventory and waste
Shortage history	Influences hospital procurement decisions
Contract manufacturing capacity	Affects supply continuity
503B outsourcing availability	May provide non-ANDA alternatives, subject to applicable law
Group purchasing organization contracts	Can determine volume access
Unit price	Matters, but supply reliability often carries greater weight

FDA’s Drug Shortages database should be monitored because injectable magnesium products can be affected by manufacturing interruptions, raw-material constraints, or facility events. [5] A supplier with redundant manufacturing and documented shortage performance may win contracts despite a higher unit price.

What commercial opportunities exist for an excipient-led strategy?

The most viable opportunity is not a new excipient for its own sake. It is a product platform that uses excipient and packaging choices to solve a documented hospital problem.

Ready-to-administer obstetric products

Magnesium sulfate is heavily associated with obstetric emergency protocols. A clearly labeled, ready-to-use bag can reduce calculation and dilution steps. High-value features include:

• Large, easy-to-read dose and concentration display
• Distinctive labeling to prevent selection errors
• Protocol-aligned volume
• Administration-set compatibility
• Room-temperature storage
• Tamper-evident packaging
• Barcode support

Low-waste hospital formats

A smaller-volume premix may reduce waste for routine replacement, while larger bags may support high-dose protocols. Offering a limited number of protocol-aligned strengths can improve utilization without creating excessive inventory burden.

Dextrose-sensitive patient segmentation

A magnesium sulfate product in normal saline or another vehicle may be preferable for patients where dextrose is undesirable. This creates a portfolio opportunity: D5W-based magnesium sulfate can be positioned as one vehicle option, not a universal replacement for saline-based products.

Supply-resilience contracts

Hospitals and group purchasing organizations may value:

• Dual-source API qualification
• More than one sterile manufacturing site
• Reserved production capacity
• Inventory buffers
• Transparent shortage communication
• Short lead times
• Equivalent presentations across facilities

This is a commercial opportunity with limited patent dependence and high procurement relevance.

How strong is the patent estate for magnesium sulfate in 5% dextrose?

The patent estate is generally weak for the basic formulation and stronger only around narrow technical implementations. A practical scorecard is:

Asset	Indicative strength
Magnesium sulfate active ingredient	Very low
5% dextrose vehicle	Very low
Basic aqueous premix	Low
Specific concentration and volume	Low to moderate
Stability-enhancing packaging	Moderate
Integrated administration device	Moderate
Manufacturing know-how	Moderate operational value
Brand, barcode, and procurement position	High commercial value but not patent exclusivity

Freedom-to-operate analysis should focus on the exact container, port, filling process, and any third-party delivery system. A generic manufacturer may avoid meaningful risk by using a conventional formulation and a distinct container architecture.

What regulatory pathway is likely for a new product?

A conventional product that matches an established reference presentation may be developed through an ANDA, subject to FDA requirements for pharmaceutical equivalence, bioequivalence where applicable, quality, sterility, labeling, and manufacturing. A materially different formulation, concentration, container, or indication may require a different regulatory strategy, potentially including a 505(b)(2) application depending on the product’s relationship to approved references. FDA’s regulatory pathway depends on the exact formulation and reference-product facts. [6]

Key development requirements include:

• API identity, assay, impurities, and water content
• Sterility and bacterial endotoxin testing
• Particulate matter testing
• Container-closure integrity
• Extractables and leachables
• Accelerated and long-term stability
• In-use and admixture compatibility, where claimed
• Process validation
• Labeling consistent with the approved reference or proposed clinical use

Key Takeaways

• Magnesium sulfate in 5% dextrose is a mature sterile injectable with limited patent protection at the basic formulation level.
• Dextrose is the main excipient and creates both positioning value and clinical limitations.
• The strongest differentiation opportunities involve ready-to-administer formats, protocol-aligned doses, packaging, labeling, stability, and supply reliability.
• Orange Book and Paragraph IV analysis must be performed against the exact approved product and application, not the ingredient name alone.
• Manufacturing validation, sterile capacity, shortage resilience, and hospital contracting are likely to matter more than composition-of-matter patents.
• A narrow patent strategy may target stability, packaging, or integrated administration systems, but trade secrets and execution are likely to provide greater practical protection.
• A portfolio containing both D5W and saline-based magnesium sulfate presentations could address broader hospital demand than a single vehicle.

FAQs

Can dextrose 5% be replaced with normal saline in magnesium sulfate injection?

Yes, saline-based magnesium sulfate products exist, but the products are not automatically interchangeable. Vehicle, concentration, labeling, osmolarity, compatibility, and clinical protocol must be evaluated separately.

Is magnesium sulfate in 5% dextrose a biologic or biosimilar product?

No. Magnesium sulfate is a chemically defined small-molecule drug. Biosimilar regulation does not apply. Market entry is governed by applicable generic or new-drug pathways.

Does a new bag design create patentable protection?

Potentially. A bag design may support patent claims if it provides a novel, nonobvious technical solution involving administration, compatibility, handling, or stability. A purely ornamental design generally provides weaker protection.

What is the main regulatory risk for a new magnesium sulfate premix?

The main risks are sterile manufacturing failure, particulate or endotoxin deviations, container-closure problems, stability failure, and inconsistent concentration. These risks can delay approval or cause supply interruption.

Is a magnesium sulfate premix attractive for contract manufacturing?

It can be attractive for a sterile manufacturer with validated low-volume liquid filling, injectable packaging capacity, and hospital distribution access. The product has limited formulation complexity, but commercial success depends on dependable supply, approved labeling, and procurement contracts.

References

1. U.S. Food and Drug Administration. (n.d.). Magnesium sulfate injection prescribing information. Drugs@FDA and DailyMed labeling resources.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2004). Guidance for industry: Sterile drug products produced by aseptic processing: Current good manufacturing practice.

5. U.S. Food and Drug Administration. (n.d.). Drug shortages. Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). Center for Drug Evaluation and Research.